The present invention relates to devices and methods for enhancing vision of a subject and, more particularly, to multi-zonal ophthalmic lenses and methods of use thereof for enhancing vision of a subject.
Intraocular lenses and other ophthalmic devices are used to restore and correct vision. For example, monofocal intraocular lenses may be used to replace the natural lens of an eye that has developed cataracts. The simplest type of monofocal intraocular lens is spherical lens in which both optical surfaces have a spherical profile. More recently, aspheric lenses have been used to enhance the visual acuity of intraocular lenses. Such aspheric lenses may be used to at least partially correct for aberrations that are produced by an opposing spherical surface and/or aberrations produced by the eye itself (e.g., positive spherical aberrations produced by the cornea of most human eyes). Examples of such lens designs are described in U.S. Pat. Nos. 6,609,793 and 7,137,702, which are herein incorporated by reference in their entirety. Lenses may also be configured to correct for chromatic aberrations inherent in most refractive lenses, for example, through the use of diffractive phase plates (e.g., U.S. Pat. Nos. 4,637,697, 5,121,979, and 6,830,332 and U.S. Patent Application Number 2004/0156014 and 2006/0098163, all of which are also herein incorporated by reference in their entirety).
When spherical intraocular lenses are used, a practitioner may, based on pre-operative ocular measurement, select a lens power that would make a subject somewhat myopic, for example choosing a lens power that provides a subject the best MTF performance or the best visual acuity for objects located at the so called “hyperfocal distance”. One advantage of this approach is an increased likelihood that the subject will have spectacle-free vision for at least one distance or range of distances. That is, if the estimated lens power is incorrect and the intraocular lens is too strong—resulting in a myopic condition—then subject will need correction of distant vision, but will have near or intermediate vision without the use of spectacles or contact lenses. Additionally, if the lens power is selected to give the subject the best MTF performance or best visual acuity for objects located at the hyperfocal distance, the subject generally has a larger range of distances over which objects will be reasonably clear, without the use of spectacles or contact lenses. The increased range provided by choosing the lens power based on the hyperfocal distance may be considered as a type of pseudo-accommodation, in that the resulting vision performance over a range of distances resembles the vision provided by the eye's natural lens prior to the onset of presbyopia.
One potential drawback to selecting the optical power of an intraocular lens based on the hyperfocal distance is that visual acuity for nighttime driving may be reduced, since the best lens performance is for objects located at the hyperfocal distance, rather than at optical infinity. However, most of the objects within the field of view under nighttime driving conditions are at optical infinity and are, therefore, slightly defocused. Since the pupil is fully dilated under these conditions, spherical aberrations may further reduce visual acuity. The effects of spherical aberrations may, however, be reduced by using aspheric lens surfaces that are configured to reduce, correct, or compensate for spherical aberrations of the lens and/or cornea.
Regardless of in-focus condition selected (e.g., at optical infinity or at the hyperfocal distance), aspheric lens surfaces serve to provide an improved visual outcome. This is because, as compared to a substantially equivalent spherical lens, aspheric lenses generally provide better visual acuity or MTF performance at all distances, and not simply at the distance corresponding to the best-focus condition. However, while an aspheric lens with a power selected for the hyperfocal distance generally provides better nighttime driving vision than a spherical lens, the visual acuity will still be reduced compared to the performance when the lens power is selected to provide best-focus at optical infinity.
Accordingly, improved monofocal ophthalmic lenses are needed that will provide both increased visual acuity under nighttime driving conditions and, under other lighting conditions, provide the relatively large depth of focus that is possible by selecting a lens power based on a hyperfocal distance.
Embodiments of the present invention are generally directed to devices and methods for providing an eye with enhanced visual performance and/or visual acuity under certain visual and/or lighting conditions, while simultaneously providing a relatively large depth of field or depth of focus under other visual and/or lighting conditions. For example, an outer portion or zone of an optic of an intraocular lens may be configured to reduce, compensate, or cancel a spherical aberrations and/or other higher order monochromatic aberrations and/or chromatic aberrations when a pupil of an eye is relatively large (e.g., under typical nighttime driving conditions), while an inner or central portion or zone of the same optic may be configured to provide better depth of field or depth of focus when the pupil is relatively small (e.g., under typical indoor or outdoor lighting conditions or under typical reading conditions). Alternatively or additionally, the outer zone may be configured to provide the best visual acuity or optical performance for objects at optical infinity, while the inner or central zone is configured to provide the best visual acuity or optical performance for closer objects, for example, objects at a hyperfocal distance from the eye. The inner or central zone of the same optic may include opposing spherical surfaces that provide a greater depth of field or depth of focus than the outer zone of the optic. Alternatively, the inner or central zone may be configure have an enhanced depth of field or enhanced depth of focus that is greater than that of a substantially equivalent spherical zone (e.g., an inner or central zone having a depth of focus that is greater than that of a spherical zone having an optical power equal to an optical power or average optical power of the inner or central zone). Exemplary embodiments of the invention presented herein are generally directed to intraocular lenses; however, embodiments of the invention may also be extended to other types of ophthalmic lenses and devices, such as corneal inlays or onlays, phakic lenses, laser vision correction (e.g., LASIK and PRK procedures), contact lenses, and the like.
One aspect of the present invention involves an ophthalmic device, such as an intraocular lens, comprising an optic having a variation in optical power over an entire clear aperture of the lens that is less than a predetermined amount and that is less than the add power of a typical refractive or diffractive multifocal intraocular lens (e.g., less than about 2 Diopters or 1.5 Diopters). The optic has an anterior surface and an opposing posterior surface, the surfaces disposed about an optical axis. The optic further comprises a central zone having a plurality of optical powers that progressively vary between a first optical power at a center of the central zone and a second optical power at a periphery of the central zone, wherein the absolute value of the difference between the first optical power and the second optical power is within a relatively small range compared to the add power of a typical refractive or diffractive multifocal intraocular lens (e.g., between about 0.25 Diopter and about 2 Diopters). The ophthalmic devices also comprises an outer zone disposed about the central zone, the outer zone comprising a third optical power and optionally an optical aberration to compensate or reduce a similar aberration of the cornea or eye of a subject or group of subject. The optical aberration may be a chromatic aberration or a monochromatic aberration such as spherical aberration, coma, or astigmatism.
Another aspect of the present invention involves a method of making an intraocular lens or other ophthalmic device, the method comprising forming an anterior surface and an opposing posterior surface, the surfaces being disposed about an optical axis and providing a clear aperture. The method also comprises forming a central zone comprising a plurality of optical powers that progressively vary between a first optical power at a center of the central zone and a second optical power at a periphery of the central zone. The method further comprises forming outer zone disposed about the central zone, the outer zone comprising a third optical power and an optionally an optical aberration. The optic has a variation in optical power over the entire clear aperture that is less than a predetermined amount and that is less than the add power of a typical multifocal intraocular lens (e.g., less than 3 Diopters or 4 Diopters, or between about 0.25 Diopter and about 2 Diopters).
Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention, provided that the features included in such a combination are not mutually inconsistent.
Embodiments of the present invention may be better understood from the following detailed description when read in conjunction with the accompanying drawings. Such embodiments, which are for illustrative purposes only, depict novel and non-obvious aspects of the invention. The drawings include the following figures:
As used herein, the term “optical power” means the ability of a lens or optic, or portion thereof, to converge or diverge light to provide a focus (real or virtual) when disposed within a media. When used in conjunction with an intraocular lens, the optical power is that of the intraocular lens when disposed within a media having a refractive index of 1.336 (generally considered to be the refractive index of the aqueous and vitreous humors of the human eye). In any event, the optical power is generally specified in units of reciprocal meters (m−1) or Diopters (D). See ISO 11979-2, which is herein incorporated by reference in its entirety. As used herein the term “focal length” means the reciprocal of the optical power, and is typically expressed in units of millimeters (mm). As used herein the term “power”, when used in reference to an optic or lens, means “optical power”. As used herein, the term “refractive power” or “refractive optical power” means the power of a lens or optic, or portion thereof, attributable to refraction of incident light. As used herein, the term “diffractive power” or “diffractive optical power” means the power of a lens or optic, or portion thereof, attributable to diffraction of incident light into one or more diffraction orders. Except where noted otherwise, the optical power of a lens or optic is from a reference plane associated with the lens or optic (e.g., a principal plane of an optic). When used in conjunction with optical power in Diopters, the term “about” or “approximately” means within plus or minus 0.25 Diopters.
Accept where noted otherwise, the phrase “optical power of an optic” or “optical power of a lens”, or similar such phrase, means a paraxial power of the optic or lens (i.e., the power near the optical axis of the optic or lens for rays of collimated light parallel to the optical axis). As used herein, the terms “power” or “optical power”, when used in reference to a portion or zone of an optic or lens, means a local power of the portion or zone, or some portion thereof. As used herein, a “spherical optic” means an optic having anterior and posterior surfaces each described by a sphere having a constant radius of curvature and is considered to have a paraxial power at the optical axis thereof and local powers over the optic that increase with increasing radius from the optical axis as a result of spherical aberration. This increase of power with increasing radius of the spherical optic is a “positive spherical aberration”. As used herein, an “aspheric optic” has at least one optical surface with a shape that deviates from a spherical shape, and is considered to have a paraxial power at the optical axis thereof and local powers that may, with increasing radius from the optical axis, increase (e.g., multifocal optic or an optic with enhanced depth of focus), remain constant (e.g., an aspheric optic configured to eliminate or cancel a spherical aberration of an opposing optical surface of the optic), or decrease (e.g., an optic configured to reduce, compensate, or cancel a spherical aberration of an opposing optical surface of the optic and/or of an optical system or eye into which the optic is placed).
As used herein, the term “near vision” means vision produced by an eye that allows a subject to focus on objects or planes that are relatively close to the subject, for example, within a range of about 25-40 cm or at a distance at which a subject would generally place printed material for the purpose of reading. As used herein, the term “distant vision” means vision produced by an eye that allows a subject to focus on objects or planes that are located at least 6 meters away from the eye. As used herein, the term “intermediate vision” means vision of objects at approximately 40 centimeters to approximately 1.5 meters from the eye or spectacle plane.
As used herein, the term “hyperfocal distance” means a distance at which, for an emmetropic eye, an add power of 0.4 Diopters in the spectacle plane of the eye provides a best MTF performance or a best visual acuity (e.g., a visual acuity of 20/20 or better, based on the standard Snellen test for visual acuity). For example, in a human eye with an axial length (AL) of 25 mm, the hyperfocal distance is 2.5 meters from the eye or about 2.5 meters from the eye, where “about” means within plus or minus 0.25 meters. As used herein, the term “emmetropic vision” or “emmetropia” means a state of vision in which an object at a distance of about 6 meters from an eye produces a visual acuity of 20/20 or better with the eye lens in a neutral or relaxed state. As used herein, the term “emmetropic eye” means an eye producing emmetropic vision. As used herein, the term “best visual acuity” means, for a given state of accommodation of an eye, a visual acuity experienced by a subject that cannot be improved by moving an object or plane further away from, or closer to, the subject. As used herein, the term “best MTF performance” means, for a given focus condition, a MTF performance produced by a lens or optical system (including an ocular system) that cannot be improved by moving an object or plane further away from, or closer to, the lens or ocular system.
As used herein, the term “clear aperture” means the opening of a lens or optic that restricts the extent of a bundle of light rays from a distant light source that can imaged or focused by the lens or optic. The clear aperture is usually circular and specified by its diameter. Thus, the clear aperture represents the full extent of the lens or optic usable in forming a image of an object, or in focusing light from a distant point source to a single focus or, in the case of a multifocal optic or lens, to a plurality of predetermined foci. It will be appreciated that the term “clear aperture” does not denote or imply a particular clarity or transmissivity of an optic or lens. For example, an optic may have a clear aperture that is approximately equal to the diameter of the optic, irrespective of whether or not a dye is used that reduces the transmission of light.
As used herein, the term “depth of field” (DOF) means a range of distances from an eye or subject over which an acceptable visual or optical performance is provided—for example, over which an acceptable amount of defocus, an acceptable MTF performance, or an acceptable visual acuity is provided. As used herein, the term “extended DOF,” as applied to an optic, means that the depth of field of the optic, or an optical system of which the optic is used, is greater than the depth of focus provided by a reference spherical optic made of the same material, and having the same paraxial power and radius of curvature for the anterior and posterior surfaces, as the optic having the extended DOF. As used herein, the term “depth of field” means the range of distances at or near an image plane or retina that corresponds to the DOF.
As used herein, the term “optical infinity” means a distance of 6 meters or greater from an optic, lens, lens system, or eye.
Referring to
When the optical power of an optic or optical system varies continuously with distance from the optical axis OA (e.g., as illustrated in
With further reference to
Referring now to
Referring to
The optic 311 comprises a central or inner zone 314 disposed about the optical axis OA and having an outer diameter Din. The optic 311 further comprises an outer zone 315 disposed about, and adjacent to, the inner zone 314 and having an outer diameter Dout and an inner diameter Din, so that the zones 314, 315 fill the entire clear aperture of the optic 311. Alternatively, the outer diameter Dout of the outer zone 315 is less than the diameter of the clear aperture of the optic 311, so that the optic 311 contains other optical features in addition to those of the zones 314, 315. In the illustrated embodiment, the zone 314 is circular when viewed from the anterior side (e.g., as illustrated in
In the illustrated embodiment, the outer diameter Dout is equal to the diameter of the clear aperture of the optic 311, which may be equal to or substantially equal to the diameter of the optic 311. Optionally, the outer diameter Dout may be smaller than the outer diameter of the optic 311, as illustrated by the dash-dotted circle in
With further reference to
As a reference, the dotted/dashed reference curve 317 represents the power variation with radius from the optical axis OA of a reference spherical optic having a paraxial power equal to the first optical power P1 of the optic 311, wherein the reference spherical optic is made of the same material and comprises anterior and posterior surfaces each having the radius of curvature equal to the radius of curvature of corresponding anterior/posterior surfaces 312, 313 of the optic 311 at the optical axis OA. The absolute value of the difference between the first optical power P1 and the second optical power P2 (e.g., |P2−P1|) is generally less than the add power of a typical multifocal intraocular lens (e.g., less than 3 or 4 Diopters, or less than about 2 Diopters). For example, the absolute difference between P1 and P2 is generally between about 0.1 Diopter and about 1.5 Diopter or between about 0.25 Diopter and about 1 Diopter. The power P1 may be a paraxial power or a base power of the optic 311, and/or the central zone 314, and may be selected to provide distant vision or emmetropia for an animal or human subject. Additionally or alternatively, the central zone 314 may comprise spherical surfaces 312, 313, wherein the power P2 is equal to or substantially equal to the power of the reference spherical optic represented by the reference curve 317 at radius rin.
In certain embodiments, the central zone 314 may comprise a plurality of distinct powers that are produced through the use of a refractive and/or diffractive surface profile. For example, the central zone may comprise a diffractive grating or phase plate that produces two distinct foci. In general, the difference in optical power between the two foci is relatively small (e.g., less than or equal to about 1 Diopter, 1.5 Diopters, or 2 Diopters), although larger Diopter differences may be incorporated if a multifocal effect is desired. In some embodiments, a relatively small difference in optical power between the two foci may be used to provide an extended depth of focus, for example, as disclosed in U.S. Provisional Patent Application No. 60/968,250, which is herein incorporated by reference in its entirety.
The profile of one or both surfaces 312, 313 may be configured to provide a radial power profile that is different from that shown in
The outer zone 315 of optic 311 shown in
Referring to
In the illustrated embodiment, the power variation of the central zone 314 matches that of a spherical optic having a paraxial power of P1; however, the variation of power of the central zone 314 may be aspheric in shape, for example, configured to produce an enhanced depth of focus that is greater than that of a spherical lens have a paraxial power equal to P1 of the optic 311.
Referring again to
Optionally, the intermediate zone 316 may be utilized to further enhance the performance of the intraocular lens 310 in some way. For example, the intermediate zone 316 may be configured to provide better performance when the intraocular lens 310 is decentered or tilted after placement within an eye, as disclosed in U.S. Patent Application Number 2004/0106992, which is herein incorporated by reference in its entirety). Alternatively, the intermediate zone may be used to control halo effects, for example, as disclosed in U.S. Patent Application Number 2006/098163. The intermediate zone 316 in the illustrated in
For the embodiments shown in
The zones 314, 315 may be configured such that the optic 311 has a variation in optical power over the entire clear aperture that is less than or equal to 1.5 Diopters or less than or equal to 1 Diopter. The total variation in optical power over the entire clear aperture may be selected in accordance with specific design parameters such as the range of pseudo-accommodation to be provided, the required visual acuity at one or more specific object distance, the zone diameters, the pupil size under certain lighting conditions, the expected variation in pupil size, a desired mixture of near, intermediate, and/or distant vision for one or more pupil sizes, and the like.
The optic 311 illustrated in
The intraocular lenses 310 may be fabricated with optical powers that vary from about 10 Diopters to about 30 Diopters in increments of about 0.5 Diopters. In some embodiments, intraocular lenses 310 may be produced that vary from about zero Diopters to about 40 Diopters or more. Alternatively or additionally, intraocular lenses 310 may be produced that have a negative optical power, for example that is within a range of less than about zero Diopters to greater than about −20 Diopters or less.
The intraocular lens 310 may generally be constructed of any of the various types of material known in the art. For example, the intraocular lens 310 may be a foldable lens made of at least one of the materials commonly used for resiliently deformable or foldable optics, such as silicone polymeric materials, acrylic polymeric materials, hydrogel-forming polymeric materials (e.g., polyhydroxyethylmethacrylate, polyphosphazenes, polyurethanes, and mixtures thereof), and the like. Other advanced formulations of silicone, acrylic, or mixtures thereof are also anticipated. Selection parameters for suitable lens materials are well known to those of skill in the art. See, for example, David J. Apple, et al., Intraocular Lenses: Evolution, Design, Complications, and Pathology, (1989) William & Wilkins, which is herein incorporated by reference. The lens material may be selected to have a relatively high refractive index, and thus provide a relatively thin optic, for example, having a center thickness in the range of about 150 microns to about 1000 microns, depending on the material and the optical power of the lens. At least portions of the intraocular lens 310, for example one or more haptics or fixation members thereof, may be constructed of a more rigid material including such polymeric materials as polypropylene, polymethylmethacrylate PMMA, polycarbonates, polyamides, polyimides, polyacrylates, 2-hydroxymethylmethacrylate, poly (vinylidene fluoride), polytetrafluoroethylene and the like; and metals such as stainless steel, platinum, titanium, tantalum, shape-memory alloys, e.g., nitinol, and the like. In some embodiments, the optic and haptic portions of the intraocular lens 310 are integrally formed of a single common material.
In certain embodiment, for example as illustrated in
where c is a base curvature of the surface portion (which is equal to 1/R, where R is the radius of curvature, k is a conic constant, and r is the radial distance from the optical axis OA. Depending on the value of k the first term is a conic section and describes a:
Alternatively, at least one of the surfaces 312, 313 within the outer zone 315 of the intraocular lens 310 may be characterized by an equation defining a modified conoid of rotation, wherein a surface sag profile varies according to the relation:
where a2, a4, . . . are constants, c is a base curvature of the surface portion (which is equal to 1/R, where R is the radius of curvature, k is a conic constant, and r is the radial distance from the optical axis OA. In certain embodiments, other portions of at least one of the surfaces 312, 313 outside the outer zone 315 (e.g., the central zone 314) may be characterized by the equation defining a conoid of rotation or by the equation defining a modified conoid of rotation, where the constant value may be different that those describing the surface 312, 313 within the outer zone 315.
It will be appreciated that the local radius of curvature of the anterior and posterior surfaces 312, 313, or some portion thereof, may be at least approximately related to a local power D at a given radius r (e.g., a power from
where nl is equal to the refractive index of the optic 311 material, no is equal to the refractive index of the medium in which the optic 311 is place (e.g., typically 1.336 in an eye), R1 is the local radius of curvature of the anterior surface 312, R2 is the local radius of curvature of the posterior surface 313, and b1 and b2 are constants for the anterior and posterior surfaces 312, 313, respectively. When one or both surfaces are described by a conoid of rotation, b1 and b2 may be set equal to 2(1+k1)(1/R1)3 and 2(1+k2)(1/R2)3, respectively, where R1 and R2 are radius of curvatures at radius r on the surfaces 312 and 313, respectively, and k1 and k2 are conic constants at radius r on the surfaces 312 and 313, respectively.
Referring to
The profile 320 has a central profile 322 that has a radius of curvature RAdd along the central portion 314 of the optic 311. The radius of curvature RAdd is configured to have a power to provide intermediate vision or a best visual acuity or best MTF for objects located at a hyperfocal distance (e.g., at 2.5 meters or at about 2.5 meters from the eye 90).
The profile 320 also includes an outer aspheric profile 325 along the outer portion 315. The aspheric profile 325 has a base curve 326 (shown by a dashed line in
At the optical axis OA, the profile 320 has a radius of R2 from the center of curvature 328 that is generally greater than the radius R1. At radius rin from the optical axis OA, the profile 320 has a radius of R3 from the center of curvature 328, while at outer radius rout from the optical axis OA, the profile 320 has a radius of R4 from the center of curvature 328.
Referring to
Referring to
In certain embodiments, the profiles shown in
Referring to
The performance of the optic 311 will now be described in terms of ray tracing characteristics. The aberration of the outer zone 315 may be selected to completely or substantially completely compensate for a spherical aberration of a cornea or eye. Alternatively, the aberration of the outer zone 315 may be selected to only partially compensate for (or over compensate for) the spherical aberration or other aberration of the cornea or eye. In this regard, it may be advantageous in certain embodiments to select the aberration of the outer zone 315 to leave a residual aberration when combined with a cornea, for example, as discussed in U.S. Pat. No. 7,350,916, which is herein incorporated by reference in its entirety. For instance, the intraocular lens 310 may comprise an outer zone 315 that has an optical power that is about 20 Diopters and a negative spherical aberration that partially correct a positive spherical aberration of the cornea, wherein the outer zone 315 has a negative spherical aberration that is between about −0.19 and about −0.202 microns, or that is about −0.156 microns. The eye may have a residual aberration that is essentially zero or is greater than zero (e.g., a residual aberration of about +0.14 microns or between about +0.006 microns and about +0.090 microns has been reported as potentially beneficial, for example, when placed in an eye or an eye model with a corneal spherical aberration of about 0.327 microns). In other embodiments, the intraocular lens 310 is configured with an outer zone 315 in which the optical power at the periphery of the zone is about 0.5 to about 0.75 Diopters less than the optical power at or near the boarder between the zones 314, 315.
As discussed above, the central zone 314 has an optical power that ranges from P1 at or near the center to P2 at or near the periphery of the zone, while the outer zone 315 has a power P3. In certain embodiments, the first optical power P1 and/or the third optical power P3 is less than the second optical power P2 by an amount that is less than or equal to about 1.5 or 2 Diopters, preferably less than or equal to about 1.0 Diopter, and in some cases less than or equal to about 0.5 Diopters. In some embodiments, the variation in optical power over the entire clear aperture (e.g., within and between the zones 314, 315) is less than or equal to about 0.5 Diopter plus the variation in optical power produces by the spherical aberrations of a spherical optic having a nominal optical power equal to that of the third optical power P3.
In the illustrated embodiment, the difference between the second optical power P2 of the central zone 314 and the first and/or third optical powers P1, P3 represents an add power ΔD, where the add power ΔD is generally smaller than the add power of a typical multifocal intraocular lens, which generally have add powers in the range of about 2 Diopters to about 4 Diopters (see, for example, U.S. Pat. Nos. 6,527,389, 5,225,858, and 6,557,992, which are herein incorporated by reference in their entirety. As used herein, the term “add power” means a change in optical power from an optical power necessary to provide distance vision. As used herein, the “add power” is the change in power at the principal plane of the intraocular lens (e.g., an intraocular lens add power of 4.0 Diopters is approximately equal to an increase in optical power of about 3.2 Diopters in the spectacle lens). Surprisingly, the use of a relatively small add power according to embodiments of the invention (e.g., of about one Diopter to about two Diopters) may beneficially provide better intermediate vision and/or near vision than if a larger add power were to be used in the central zone 314 (e.g., an add power of about 3 or 4 Diopters). This improved performance may, for example, be due to relatively low noise from halo effects when using a lower add power of about 1.0 to about 2.0 Diopters.
Embodiments of the intraocular lens 310 may be configured to provide a pupil 101 dependent visual acuity performance that is preferred over either a spherical intraocular lens such as the intraocular lens 110 or an aspheric intraocular lens such as the intraocular lens 210. For example, both zones 314, 315 in the illustrated embodiment focus light onto or near the retina 104 when the pupil 101 is relatively large, for instance under low lighting conditions or night time driving conditions. Because at least one of the surfaces 312, 313 in the vicinity of the outer zone 315 is aspheric, most of the light from distant objects entering the optic 311 is advantageously focused to substantially a single focus or point. This may provide better visual acuity than is generally possible with an optic having only spherical surfaces (e.g., the intraocular lens 110 illustrated in
The intraocular lens 310 is also able to provide a pseudo-accommodative benefits under bright or intermediate lighting conditions in which the pupil 101 is small, since under these conditions all or most of the light entering the intraocular lens 310 passes through the central zone 314. Thus, the intraocular lens 310 is able to advantageously provide pseudo-accommodative benefits without significantly compromising the advantages of an aspheric intraocular lens over a spherical intraocular lens during night driving conditions.
The performance of the intraocular lens 310 under differing pupil sizes may be controlled by selecting the diameter of the central zone 314. For example, the central zone 314 may be configured to have an outer diameter D that is about the size of a typical pupil that is fully contracted, such as under sunny outdoor lighting conditions (e.g., the outer diameter D of the central zone 314 may about 1 millimeter, about 2 millimeters, or about 3 millimeters, or between about 2 millimeters and about 3 millimeters, depending on the relative performance desired between near, intermediate, and distant vision). In other embodiments, the diameter D is selected to provide predetermined areas ratios of the central and outer zones 314, 315 under specific lighting conditions or pupil sizes. Thus, the diameter D may be selected to provide a predetermined performance balance of distant visual acuity and enhanced DOF (or pseudo-accommodation) as a function of pupil size.
To illustrate one way of configuring the central zone 314 to provide pseudo-accommodation, reference is now made to
As illustrated in
The paraxial ray 360c comes to focus on the retina 104 at the focus 362c, so that objects optical infinity are just focused and, therefore, at least somewhat resolved by the eye 90. Referring to the discussion above with regards to
In some embodiments, at least one of the surfaces of the central zone 314 has a positive spherical aberration that is greater than or less than that of an equivalent spherical surface having substantially the same focal length or optical power. In general the amount of positive spherical aberration may be selected to provide a predetermined DOF and/or add power, as represented by ΔD in
Referring to
In certain embodiments, a method of making an intraocular lens comprises forming an anterior surface and an opposing posterior surface, the surfaces being disposed about an optical axis to provide a clear aperture. The method further comprises forming a central zone comprising a plurality of optical powers that progressively vary between a first optical power at a center of the central zone and a second optical power at a periphery of the central zone, the absolute value of the difference between the first optical power and the second optical power being between about 0.25 Diopter and about 1 Diopter. The method also comprises forming outer zone disposed about the central zone, the outer zone comprising a third optical power and an optional negative spherical aberration. The optic resulting from the method has a variation in optical power over the entire clear aperture that is less than about 1 Diopter.
While embodiments of the invention have been disclosed for an IOL suitable providing enhanced performance under non-optimal conditions, such as when the IOL is decentered from the optical axis of the eye, those skilled in the art will appreciate that embodiments of the invention are suitable for other ocular devices such as contact lenses and corneal implants. For instance, the method of designing a multi-zonal monofocal IOL may be adapted for improving the performance of contact lenses, which are known to move to different positions during use relative to the optical axis of the eye.
This application claims priority to and is a divisional of U.S. patent application Ser. No. 14/642,385, filed Mar. 9, 2015, now U.S. Pat. No. 10,265,162, which is a divisional application of, and claims priority to, U.S. patent application Ser. No. 12/398,933 filed on Mar. 5, 2009, now U.S. Pat. No. 8,974,526, which is a continuation-in-part application of, and claims priority to, U.S. patent application Ser. No. 11/845,682, filed Aug. 27, 2007, now abandoned, the entire contents of each of which applications are hereby incorporated by reference in their entirety for all purposes as if fully set forth herein.
Number | Name | Date | Kind |
---|---|---|---|
2077092 | Broder | Apr 1937 | A |
3305294 | Alvarez | Feb 1967 | A |
3367734 | Bystricky et al. | Feb 1968 | A |
3735685 | Plummer | May 1973 | A |
4010496 | Neefe | Mar 1977 | A |
4077071 | Freeman | Mar 1978 | A |
4093361 | Erickson et al. | Jun 1978 | A |
4134160 | Bayers | Jan 1979 | A |
4162122 | Cohen | Jul 1979 | A |
4174543 | Kelman | Nov 1979 | A |
4210391 | Cohen et al. | Jul 1980 | A |
4249272 | Poler | Feb 1981 | A |
4254509 | Tennant | Mar 1981 | A |
4254510 | Tennant | Mar 1981 | A |
4316293 | Bayers | Feb 1982 | A |
4319564 | Karickhoff | Mar 1982 | A |
4338005 | Cohen | Jul 1982 | A |
4340283 | Cohen et al. | Jul 1982 | A |
4370760 | Kelman | Feb 1983 | A |
4377873 | Reichert | Mar 1983 | A |
4402579 | Poler | Sep 1983 | A |
4403353 | Tennant | Sep 1983 | A |
4404694 | Kelman | Sep 1983 | A |
4409691 | Levy | Oct 1983 | A |
4424597 | Schlegel | Jan 1984 | A |
4446581 | Blake | May 1984 | A |
4480340 | Shepard | Nov 1984 | A |
4500382 | Foster | Feb 1985 | A |
4504982 | Burk | Mar 1985 | A |
4551864 | Akhavi | Nov 1985 | A |
4556998 | Siepser | Dec 1985 | A |
4560383 | Leiske | Dec 1985 | A |
4564484 | Neefe | Jan 1986 | A |
4580882 | Nuchman et al. | Apr 1986 | A |
4593981 | Scilipoti | Jun 1986 | A |
4605409 | Kelman | Aug 1986 | A |
4605411 | Fedorov et al. | Aug 1986 | A |
4629460 | Dyer | Dec 1986 | A |
4629462 | Feaster | Dec 1986 | A |
4636049 | Blaker | Jan 1987 | A |
4637697 | Freeman | Jan 1987 | A |
4642112 | Freeman | Feb 1987 | A |
4655565 | Freeman | Apr 1987 | A |
4673406 | Schlegel | Jun 1987 | A |
4676791 | Lemaster et al. | Jun 1987 | A |
4676792 | Praeger | Jun 1987 | A |
4681102 | Bartell | Jul 1987 | A |
4687484 | Kaplan | Aug 1987 | A |
4687485 | Lim et al. | Aug 1987 | A |
RE32525 | Pannu | Oct 1987 | E |
4725277 | Bissonette | Feb 1988 | A |
4734095 | Siepser | Mar 1988 | A |
4769033 | Nordan | Sep 1988 | A |
4778462 | Grendahl | Oct 1988 | A |
4781717 | Grendahl | Nov 1988 | A |
4787903 | Grendahl | Nov 1988 | A |
4787904 | Severin et al. | Nov 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4798609 | Grendahl | Jan 1989 | A |
4828558 | Kelman | May 1989 | A |
4834748 | McDonald | May 1989 | A |
4863539 | Lee et al. | Sep 1989 | A |
4898461 | Portney | Feb 1990 | A |
4906246 | Grendahl | Mar 1990 | A |
4932970 | Portney | Jun 1990 | A |
4995714 | Cohen | Feb 1991 | A |
4995715 | Cohen | Feb 1991 | A |
4997442 | Barrett | Mar 1991 | A |
5016977 | Baude et al. | May 1991 | A |
5019097 | Knight et al. | May 1991 | A |
5047052 | Dubroff | Sep 1991 | A |
5050981 | Roffman | Sep 1991 | A |
5054905 | Cohen | Oct 1991 | A |
5056908 | Cohen | Oct 1991 | A |
5066301 | Wiley | Nov 1991 | A |
5071432 | Baikoff | Dec 1991 | A |
5078742 | Dahan | Jan 1992 | A |
5089023 | Swanson | Feb 1992 | A |
5096285 | Silberman | Mar 1992 | A |
5112351 | Christie et al. | May 1992 | A |
5114220 | Baude et al. | May 1992 | A |
5117306 | Cohen | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5121979 | Cohen | Jun 1992 | A |
5121980 | Cohen | Jun 1992 | A |
5133749 | Nordan | Jul 1992 | A |
5144483 | Cohen | Sep 1992 | A |
5147395 | Willis | Sep 1992 | A |
5147397 | Christ et al. | Sep 1992 | A |
5158572 | Nielsen | Oct 1992 | A |
5166711 | Portney | Nov 1992 | A |
5166712 | Portney | Nov 1992 | A |
5181053 | Brown | Jan 1993 | A |
5184405 | Cress | Feb 1993 | A |
5191366 | Kashiwagi | Mar 1993 | A |
5197981 | Southard | Mar 1993 | A |
5201763 | Brady et al. | Apr 1993 | A |
5203790 | McDonald | Apr 1993 | A |
5217491 | Vanderbilt | Jun 1993 | A |
5220359 | Roffman | Jun 1993 | A |
5225858 | Portney | Jul 1993 | A |
5225997 | Lederer et al. | Jul 1993 | A |
5229797 | Futhey et al. | Jul 1993 | A |
5258025 | Fedorov et al. | Nov 1993 | A |
5270744 | Portney | Dec 1993 | A |
5278592 | Marie et al. | Jan 1994 | A |
5384606 | Koch et al. | Jan 1995 | A |
5387970 | Neubert et al. | Feb 1995 | A |
5408281 | Zhang | Apr 1995 | A |
5433745 | Graham et al. | Jul 1995 | A |
5476513 | Brady et al. | Dec 1995 | A |
5479220 | Komatsu et al. | Dec 1995 | A |
5485228 | Roffman et al. | Jan 1996 | A |
5521656 | Portney | May 1996 | A |
5567365 | Weinschenk, III et al. | Oct 1996 | A |
5571177 | Deacon et al. | Nov 1996 | A |
5589024 | Blake | Dec 1996 | A |
5620720 | Glick et al. | Apr 1997 | A |
5628796 | Suzuki | May 1997 | A |
5652638 | Roffman et al. | Jul 1997 | A |
5657108 | Portney | Aug 1997 | A |
5684560 | Roffman et al. | Nov 1997 | A |
5691800 | Iki et al. | Nov 1997 | A |
5699142 | Lee et al. | Dec 1997 | A |
5715031 | Roffman et al. | Feb 1998 | A |
5716403 | Tran et al. | Feb 1998 | A |
5748282 | Freeman | May 1998 | A |
5754270 | Rehse et al. | May 1998 | A |
5760871 | Kosoburd et al. | Jun 1998 | A |
5766244 | Binder | Jun 1998 | A |
5777719 | Williams et al. | Jul 1998 | A |
5796462 | Roffman et al. | Aug 1998 | A |
5798817 | De Carle | Aug 1998 | A |
5801807 | Satake et al. | Sep 1998 | A |
5864378 | Portney | Jan 1999 | A |
5864379 | Dunn | Jan 1999 | A |
5877839 | Portney | Mar 1999 | A |
5895422 | Hauber | Apr 1999 | A |
5919229 | Portney | Jul 1999 | A |
5928282 | Nigam | Jul 1999 | A |
5968094 | Werblin et al. | Oct 1999 | A |
6007747 | Blake et al. | Dec 1999 | A |
6015435 | Valunin et al. | Jan 2000 | A |
6024447 | Portney | Feb 2000 | A |
6030077 | Sawano et al. | Feb 2000 | A |
6051024 | Cumming | Apr 2000 | A |
6055111 | Nomura et al. | Apr 2000 | A |
6082856 | Dunn et al. | Jul 2000 | A |
6086203 | Blum et al. | Jul 2000 | A |
6106118 | Menezes | Aug 2000 | A |
6126283 | Wen et al. | Oct 2000 | A |
6126286 | Portney | Oct 2000 | A |
6129759 | Chambers | Oct 2000 | A |
6142625 | Sawano et al. | Nov 2000 | A |
6176579 | Mandell | Jan 2001 | B1 |
6179870 | Sourdille et al. | Jan 2001 | B1 |
6186625 | Portney | Feb 2001 | B1 |
6210005 | Portney | Apr 2001 | B1 |
6221105 | Portney | Apr 2001 | B1 |
6224211 | Gordon | May 2001 | B1 |
6235055 | Chu | May 2001 | B1 |
6260966 | Sawano et al. | Jul 2001 | B1 |
6261321 | Kellan | Jul 2001 | B1 |
6286956 | Oyama et al. | Sep 2001 | B1 |
6319282 | Nishi | Nov 2001 | B1 |
6325509 | Hodur et al. | Dec 2001 | B1 |
6338559 | Williams et al. | Jan 2002 | B1 |
6390622 | Muckenhirn et al. | May 2002 | B1 |
6409339 | Wanders | Jun 2002 | B1 |
6409340 | Portney | Jun 2002 | B1 |
6419697 | Kelman | Jul 2002 | B1 |
6428573 | Barnett | Aug 2002 | B2 |
6454408 | Morris et al. | Sep 2002 | B1 |
6457826 | Lett | Oct 2002 | B1 |
6464355 | Gil | Oct 2002 | B1 |
6474814 | Griffin | Nov 2002 | B1 |
6488708 | Sarfarazi | Dec 2002 | B2 |
6491721 | Freeman et al. | Dec 2002 | B2 |
6511178 | Roffman et al. | Jan 2003 | B1 |
6527389 | Portney | Mar 2003 | B2 |
6533416 | Fermigier et al. | Mar 2003 | B1 |
6536899 | Fiala | Mar 2003 | B1 |
6537317 | Steinert et al. | Mar 2003 | B1 |
6540353 | Dunn | Apr 2003 | B1 |
6547822 | Lang | Apr 2003 | B1 |
6554859 | Lang et al. | Apr 2003 | B1 |
6557992 | Dwyer et al. | May 2003 | B1 |
6596025 | Portney | Jul 2003 | B2 |
6598606 | Terwee et al. | Jul 2003 | B2 |
6609793 | Norrby et al. | Aug 2003 | B2 |
6638305 | Laguette | Oct 2003 | B2 |
6663240 | Patel | Dec 2003 | B2 |
6705729 | Piers et al. | Mar 2004 | B2 |
6709102 | Duppstadt | Mar 2004 | B2 |
6764179 | Sakai et al. | Jul 2004 | B2 |
6797003 | Blake et al. | Sep 2004 | B1 |
6802605 | Cox et al. | Oct 2004 | B2 |
6808262 | Chapoy et al. | Oct 2004 | B2 |
6814439 | Portney | Nov 2004 | B2 |
6830332 | Piers et al. | Dec 2004 | B2 |
6846326 | Zadno-Azizi et al. | Jan 2005 | B2 |
6851803 | Wooley et al. | Feb 2005 | B2 |
6871953 | Mandell et al. | Mar 2005 | B1 |
6874887 | Tyson | Apr 2005 | B2 |
6883915 | Ye et al. | Apr 2005 | B2 |
6899425 | Roffman et al. | May 2005 | B2 |
6923539 | Simpson et al. | Aug 2005 | B2 |
6923540 | Ye et al. | Aug 2005 | B2 |
6986578 | Jones | Jan 2006 | B2 |
7004585 | Lindacher | Feb 2006 | B2 |
7018409 | Glick et al. | Mar 2006 | B2 |
7036931 | Lindacher et al. | May 2006 | B2 |
7040757 | Hall et al. | May 2006 | B2 |
7048760 | Cumming | May 2006 | B2 |
7052133 | Lindacher et al. | May 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7073906 | Portney | Jul 2006 | B1 |
7080906 | Lindacher et al. | Jul 2006 | B2 |
7137702 | Piers et al. | Nov 2006 | B2 |
7156516 | Morris et al. | Jan 2007 | B2 |
7178918 | Griffin | Feb 2007 | B2 |
7188949 | Bandhauer et al. | Mar 2007 | B2 |
7204849 | Portney | Apr 2007 | B2 |
7241311 | Norrby et al. | Jul 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7293873 | Dai et al. | Nov 2007 | B2 |
7365917 | Zalevsky | Apr 2008 | B2 |
7370962 | Roffman et al. | May 2008 | B2 |
7377640 | Piers et al. | May 2008 | B2 |
7381221 | Lang et al. | Jun 2008 | B2 |
7441894 | Zhang et al. | Oct 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455407 | Neal et al. | Nov 2008 | B2 |
7475986 | Dai et al. | Jan 2009 | B2 |
7615073 | Deacon et al. | Nov 2009 | B2 |
7616330 | Neal et al. | Nov 2009 | B2 |
7713299 | Brady et al. | May 2010 | B2 |
7794497 | Brady et al. | Sep 2010 | B2 |
7857451 | Thibos et al. | Dec 2010 | B2 |
7871162 | Weeber | Jan 2011 | B2 |
7993398 | Deacon et al. | Aug 2011 | B2 |
8002827 | Deacon et al. | Aug 2011 | B2 |
8018164 | Shannon et al. | Sep 2011 | B2 |
8042942 | Kaga et al. | Oct 2011 | B2 |
8147062 | Kaga et al. | Apr 2012 | B2 |
8162477 | Carimalo et al. | Apr 2012 | B2 |
8231219 | Weeber | Jul 2012 | B2 |
8240847 | Holden et al. | Aug 2012 | B2 |
8241354 | Hong et al. | Aug 2012 | B2 |
8382281 | Weeber | Feb 2013 | B2 |
8430508 | Weeber | Apr 2013 | B2 |
8480228 | Weeber | Jul 2013 | B2 |
8529559 | Liang | Sep 2013 | B2 |
8573775 | Weeber | Nov 2013 | B2 |
8632187 | Franques et al. | Jan 2014 | B1 |
8647383 | Sanger et al. | Feb 2014 | B2 |
8672472 | Holden et al. | Mar 2014 | B2 |
8672474 | Lindacher et al. | Mar 2014 | B2 |
8747466 | Weeber et al. | Jun 2014 | B2 |
8770745 | Lindacher et al. | Jul 2014 | B2 |
8857982 | Franques et al. | Oct 2014 | B2 |
8862447 | Weeber | Oct 2014 | B2 |
8894706 | Portney | Nov 2014 | B2 |
8974526 | Bogaert | Mar 2015 | B2 |
9039172 | Lindacher et al. | May 2015 | B2 |
9265603 | Sanger et al. | Feb 2016 | B2 |
9335563 | Weeber | May 2016 | B2 |
9477097 | Holden et al. | Oct 2016 | B2 |
20010035935 | Bhalakia et al. | Nov 2001 | A1 |
20010051825 | Peterson | Dec 2001 | A1 |
20020063848 | Fiala | May 2002 | A1 |
20020118337 | Perrott et al. | Aug 2002 | A1 |
20020173846 | Blake et al. | Nov 2002 | A1 |
20020196408 | Bhalakia et al. | Dec 2002 | A1 |
20020196412 | Abitbol | Dec 2002 | A1 |
20030063254 | Piers et al. | Apr 2003 | A1 |
20030076478 | Cox | Apr 2003 | A1 |
20030171808 | Phillips | Sep 2003 | A1 |
20030199976 | Portney | Oct 2003 | A1 |
20040054358 | Cox | Mar 2004 | A1 |
20040054408 | Glick et al. | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040085515 | Roffman et al. | May 2004 | A1 |
20040106992 | Lang et al. | Jun 2004 | A1 |
20040111153 | Woods et al. | Jun 2004 | A1 |
20040150790 | Roffman et al. | Aug 2004 | A1 |
20040156013 | Lindacher et al. | Aug 2004 | A1 |
20040156014 | Piers et al. | Aug 2004 | A1 |
20040167622 | Sunalp et al. | Aug 2004 | A1 |
20040207807 | Lindacher | Oct 2004 | A1 |
20040237971 | Radhakrishnan et al. | Dec 2004 | A1 |
20040246440 | Andino et al. | Dec 2004 | A1 |
20050096226 | Stock et al. | May 2005 | A1 |
20050125056 | Deacon et al. | Jun 2005 | A1 |
20050128432 | Altmann | Jun 2005 | A1 |
20050203619 | Altmann | Sep 2005 | A1 |
20050251254 | Brady et al. | Nov 2005 | A1 |
20050267575 | Nguyen et al. | Dec 2005 | A1 |
20060009816 | Fang et al. | Jan 2006 | A1 |
20060030938 | Altmann | Feb 2006 | A1 |
20060066808 | Blum et al. | Mar 2006 | A1 |
20060068453 | Altieri | Mar 2006 | A1 |
20060109421 | Ye et al. | May 2006 | A1 |
20060116763 | Simpson | Jun 2006 | A1 |
20060116764 | Simpson | Jun 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060238702 | Glick et al. | Oct 2006 | A1 |
20060244904 | Hong et al. | Nov 2006 | A1 |
20060244916 | Guillon | Nov 2006 | A1 |
20060279700 | Liang | Dec 2006 | A1 |
20070052920 | Stewart et al. | Mar 2007 | A1 |
20070129803 | Cumming et al. | Jun 2007 | A1 |
20070171362 | Simpson et al. | Jul 2007 | A1 |
20070182924 | Hong et al. | Aug 2007 | A1 |
20070258143 | Portney | Nov 2007 | A1 |
20070268453 | Hong et al. | Nov 2007 | A1 |
20080018910 | Neal et al. | Jan 2008 | A1 |
20080030677 | Simpson | Feb 2008 | A1 |
20080161914 | Brady et al. | Jul 2008 | A1 |
20080231809 | Haigis | Sep 2008 | A1 |
20080273169 | Blum et al. | Nov 2008 | A1 |
20080291393 | Menezes | Nov 2008 | A1 |
20090012609 | Geraghty et al. | Jan 2009 | A1 |
20090036980 | Norrby et al. | Feb 2009 | A1 |
20090051870 | Lindacher et al. | Feb 2009 | A1 |
20090051876 | Seiler et al. | Feb 2009 | A1 |
20090062911 | Bogaert | Mar 2009 | A1 |
20090088840 | Simpson et al. | Apr 2009 | A1 |
20090164008 | Hong et al. | Jun 2009 | A1 |
20090210054 | Weeber et al. | Aug 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090279048 | Hong et al. | Nov 2009 | A1 |
20090303433 | Shimojo | Dec 2009 | A1 |
20090323020 | Zhao et al. | Dec 2009 | A1 |
20100016965 | Hong et al. | Jan 2010 | A1 |
20100036489 | Lindacher et al. | Feb 2010 | A1 |
20100066973 | Portney | Mar 2010 | A1 |
20100082017 | Zickler et al. | Apr 2010 | A1 |
20100097569 | Weeber et al. | Apr 2010 | A1 |
20100100178 | Weeber et al. | Apr 2010 | A1 |
20100161048 | Schaper, Jr. | Jun 2010 | A1 |
20100161051 | Hong | Jun 2010 | A1 |
20100274234 | Liang | Oct 2010 | A1 |
20100315589 | Portney | Dec 2010 | A1 |
20110157548 | Lesage et al. | Jun 2011 | A1 |
20120140166 | Zhao | Jun 2012 | A1 |
20120143326 | Canovas et al. | Jun 2012 | A1 |
20120320334 | Ho et al. | Dec 2012 | A1 |
20140135919 | Gontijo et al. | May 2014 | A1 |
20140168602 | Weeber et al. | Jun 2014 | A1 |
20150182329 | Bogaert | Jul 2015 | A1 |
20150297343 | Hehn | Oct 2015 | A1 |
20150342727 | Fernández Gutiérrez et al. | Dec 2015 | A1 |
20160062144 | Brennan et al. | Mar 2016 | A1 |
20160062145 | Brennan et al. | Mar 2016 | A1 |
20160299355 | Biemold et al. | Oct 2016 | A1 |
20170216020 | Weeber et al. | Aug 2017 | A1 |
20190004221 | Weeber et al. | Jan 2019 | A1 |
Number | Date | Country |
---|---|---|
735664 | Jul 2001 | AU |
2010212408 | Sep 2010 | AU |
2012362545 | Jul 2015 | AU |
2722274 | Oct 2009 | CA |
2787997 | Feb 2015 | CA |
2901889 | Feb 2016 | CA |
1035363 | Sep 1989 | CN |
1039487 | Feb 1990 | CN |
1406120 | Mar 2003 | CN |
1833192 | Sep 2006 | CN |
8107675 | Jul 1981 | DE |
3439551 | Apr 1986 | DE |
226400 | Jun 1987 | EP |
227357 | Jul 1987 | EP |
0343067 | Nov 1989 | EP |
0457553 | Nov 1991 | EP |
681198 | Nov 1995 | EP |
742466 | Nov 1996 | EP |
900403 | Mar 1999 | EP |
0926531 | Jun 1999 | EP |
949529 | Oct 1999 | EP |
957331 | Nov 1999 | EP |
1424049 | Jun 2004 | EP |
1310267 | Jan 2008 | EP |
2033596 | Mar 2009 | EP |
1424049 | Jun 2009 | EP |
2182891 | Apr 2014 | EP |
2745711 | Sep 1997 | FR |
H0255314 | Feb 1990 | JP |
4126144 | Apr 1992 | JP |
11503250 | Mar 1999 | JP |
2000511439 | Sep 2000 | JP |
2004537332 | Dec 2004 | JP |
8603961 | Jul 1986 | WO |
8700299 | Jan 1987 | WO |
8809950 | Dec 1988 | WO |
9222000 | Dec 1992 | WO |
9222264 | Dec 1992 | WO |
9303409 | Feb 1993 | WO |
9507487 | Mar 1995 | WO |
9856315 | Dec 1998 | WO |
0008516 | Feb 2000 | WO |
0019906 | Apr 2000 | WO |
0027315 | May 2000 | WO |
0111418 | Feb 2001 | WO |
0118592 | Mar 2001 | WO |
0135868 | May 2001 | WO |
0154569 | Aug 2001 | WO |
0163344 | Aug 2001 | WO |
0182839 | Nov 2001 | WO |
0189424 | Nov 2001 | WO |
0221194 | Mar 2002 | WO |
02074210 | Sep 2002 | WO |
02084381 | Oct 2002 | WO |
03009053 | Jan 2003 | WO |
02084381 | Oct 2003 | WO |
2004034129 | Apr 2004 | WO |
2004068214 | Aug 2004 | WO |
04089252 | Oct 2004 | WO |
2004090611 | Oct 2004 | WO |
2004096014 | Nov 2004 | WO |
05019906 | Mar 2005 | WO |
06025726 | Mar 2006 | WO |
2006032263 | Mar 2006 | WO |
2006047698 | May 2006 | WO |
06060477 | Jun 2006 | WO |
2006060480 | Jun 2006 | WO |
2007067872 | Jun 2007 | WO |
2007092948 | Aug 2007 | WO |
2007133384 | Nov 2007 | WO |
2008045847 | Apr 2008 | WO |
2008083283 | Jul 2008 | WO |
2009017403 | Feb 2009 | WO |
2009020963 | Feb 2009 | WO |
2009029515 | Mar 2009 | WO |
2009058755 | May 2009 | WO |
2009076670 | Jun 2009 | WO |
2009137491 | Nov 2009 | WO |
2010009254 | Jan 2010 | WO |
2010009257 | Jan 2010 | WO |
2010054255 | May 2010 | WO |
2013018379 | Feb 2013 | WO |
2014033543 | Mar 2014 | WO |
2014033543 | Jun 2014 | WO |
Entry |
---|
Morlock, R., et al., “Patient-Reported Spectacle Independence Questionnaire (PRSIQ): Development and Validation,” American Journal of Ophthalmology, Jun. 2017, vol. 178, pp. 101-114. |
Alfonso J.F., et al., “Prospective Study of the Acri.LISA Bifocal Intraocular Lens,” Journal of Cataract Refractive Surgery, Nov. 2007, vol. 33 (11), pp. 1930-1935. |
Alio J.L., et al., “Phakic Anterior Chamber Lenses for the Correction of Myopia: A 7-Year Cumulative Analysis of Complications in 263 Cases,” Ophthalmology, Mar. 1999, vol. 106 (3), pp. 458-466. |
Apple D.J., et al., “Anterior Chamber Lenses Part 1: Complications and Pathology and a Review of Designs,” Journal of Cataract Refractive Surgery, Mar. 1987, vol. 13 (2), pp. 157-174. |
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 22 (36), pp. 205-221. |
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 36 (1), pp. 21-36. |
Baikoff G., et al., “Angle-fixated Anterior Chamber Phakic Intraocular Lens for Myopia 7 to -19 Diopters,” Journal of Refractive Surgery, May-Jun. 1998, vol. 14 (3), pp. 282-292. |
Canovas C., et al., “Hybrid Adaptive-Optics Visual Simulator,” Optical Letters, Jan. 15, 2010, vol. 35 (2), pp. 196-198. |
Cheng X., et al., “Predicting Subjective Judgment of Best Focus with Objective Image Quality Metrics,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 310-321. |
CILCO Advertisement Brochure, Oct. 1982, 3 pages. |
Cohen A.L., “Practical Design of a Bifocal Hologram Contact Lens or Intraocular Lens,” Applied Optics, Jul. 1, 1992, vol. 31 (19), pp. 3750-3754. |
De Almeida M.S., et al., “Different Schematic Eyes and their Accuracy to the in Vivo Eye: A Quantitative Comparison Study,” Brazilian Journal of Physics, Jun. 2007, vol. 37 (2A), 10 pages. |
Diffractive Lenses for Extended Depth of Focus and Presbyopic Correction, Presentation from Wavefront Congress held on Feb. 15, 2008, Rochester, New York. |
Doskolovich L.L., et al., “Special Diffractive Lenses,” Lens and Optical Systems Design, Apr. 1992, vol. 1780, pp. 393-402. |
European Search Report for Application No. EP11165087, dated Jul. 22, 2011, 6 pages. |
European Search Report for Application No. EP89304883, dated Sep. 3, 1990, 1 page. |
Kim J.H., et al., “The Analysis of Predicted Capsular Bag Diameter using Modified Model of Capsule Measuring Ring in Asians,” Clinical and Experimental Ophthalmology, Apr. 2008, vol. 36 (3), pp. 238-244. |
Liou H.L., et al., “Anatomically Accurate, Finite Model Eye for Optical Modeling,” Journal of Optical Society of America, Aug. 1997, vol. 14 (8), pp. 1684-1695. |
Liou H.L., et al., “The Prediction of Spherical Aberration with Schematic Eyes,” Ophthalmic and Physiological Optics, Jan. 1996, vol. 16 (4), pp. 348-354. |
Marinho A., “Results are Encouraging for Phakic IOLs, but More Work is needed,” Refractive Surgery, Feb. 2000, p. 12, 15. |
Marsack J.D., et al., “Metrics of Optical Quality Derived from Wave Aberrations Predict Visual Performance,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 322-328. |
Menapace R., “The Capsular Tension Rings,” Journal of Cataract & Refractive Surgery, Dec. 10, 2008, Chap. 3, pp. 27-44. |
Monsoriu J.A., et al., “Devil's Lenses,” Optics Express, Oct. 17, 2007, vol. 15 (21), pp. 13858-13864. |
Navarro R., et al., “Accommodation-Dependent Model of the Human Eye with Aspherics,” Journal of the Optical Society of America, Aug. 1985, vol. 2 (8), pp. 1273-1281. |
Nio Y.K., et al., “Effect of Intraocular Lens Implantation on Visual Acuity, Contrast Sensitivity, and Depth of Focus,” Journal of Cataract and Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2073-2081. |
Norrby S., et al., “Model Eyes for Evaluation of Intraocular Lenses,” Applied Optics, Sep. 7, 2007, vol. 46 (26), pp. 6595-6605. |
Olsen T., “Simple Method to Calculate the Surgically Induced Refractive Change,” Journal of Cataract & Refractive Surgery, Mar. 1993, vol. 19 (2), pp. 319-320. |
Piers P.A., et al., “Eye Models for the Prediction of Contrast Vision in Patients with New Intraocular Lens Designs,” Optics Letters, Apr. 1, 2004, vol. 29 (7), pp. 733-735. |
Piers P.A., et al., “Theoretical Comparison of Aberration-Correcting Customized and Aspheric Intraocular Lenses,” Journal of Refractive Surgery, Apr. 2007, vol. 23 (4), pp. 374-384. |
Praeger D.L., “Praeger Technique for the Insertion of the Copeland Radial IOL Posterior Chamber Placement,” Copeland Lens, 1982, 7 pages. |
Siedlecki D., et al., “Radial Gradient index Intraocular Lens: a Theoretical Model,” Journal of Modern Optics, Feb. 20-Mar. 10, 2008, vol. 55 (4-5), pp. 639-647. |
Strenn K., et al., “Capsular bag Shrinkage after Implantation of an Open-Loop Silicone Lens and a Poly(methyl methacrylate) Capsule Tension Ring,” Journal of Cataract and Refractive Surgery, Dec. 1997, vol. 23 (10), pp. 1543-1547. |
Tehrani M., et al., “Capsule Measuring Ring to Predict Capsular Bag Diameter and Follow its Course after Foldable Intraocular Lens Implantation,” Journal of Cataract Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2127-2134. |
Terwee T., et al., “Visualization of the Retinal Image in an Eye Model With Spherical and Aspheric, Diffractive, and Refractive Multifocal Intraocular Lenses,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 223-232. |
Van Den Berg T.J., “Analysis of Intraocular Straylight, Especially in Relation to Age,” Optometry and Vision Science, Feb. 1995, vol. 72 (2), pp. 52-59. |
Van Meeteren A., “Calculations on the Optical Modulation Transfer Function of the Human Eye for White Light,” Optica Acta, May 1974, vol. 21 (5), pp. 395-412. |
Vass C., et al., “Prediction of Pseudophakic Capsular bag Diameter based on Biometric Variables,” Journal of Cataract and Refractive Surgery, Oct. 1999, vol. 25 (10), pp. 1376-1381. |
Venter, J.A., et al., “Visual Outcomes and Patient Satisfaction with a Rotational Asymmetric Refractive Intraocular Lens for Emmetropic Presbyopia,” Cataract & Refractive Surgery, Mar. 2015, vol. 41 (3), pp. 585-593. |
Villegas E.A., et al., “Correlation between Optical and Psychophy, Sical Parameters as a Function of Defocus,” Optometry and Vision Science, Jan. 1, 2002, vol. 79 (1), pp. 60-67. |
Atchinson D.A., “Optical Design of Intraocular Lenses. I. On-Axis Performance,” American Academy of Optometry, 1989, vol. 66 (8), pp. 492-506. |
Packer M., et al., “Prospective Randomized Trial of an Anterior Surface Modified Prolate Intraocular Lens,” Journal of Refractive Surgery. 2002, vol. 18 (6), pp. 692-696. |
Zemax, Optical Design Program User's Guide, Nov. 1, 2004, Part 1 of 2 and Chapter 1-11, Retrieved from the Internet: URL: www.itsabook.com. |
Wolffsohn J.S., et al., “Visual Function in Patient's Implanted with a Non-Concentric Multifocal Intraocular Lens,” ver 2.1, Nov. 18, 2004. |
Number | Date | Country | |
---|---|---|---|
20190247182 A1 | Aug 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14642385 | Mar 2015 | US |
Child | 16390527 | US | |
Parent | 12398933 | Mar 2009 | US |
Child | 14642385 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11845682 | Aug 2007 | US |
Child | 12398933 | US |